APLNR抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colorectal cancer tissue using P06951(EPHX1 Antibody) at dilution 1/75. (Original magnification: ×200)    

  
  

The APLNR (Apelin Receptor) antibody is a research tool targeting the apelin receptor, a class A G protein-coupled receptor (GPCR) encoded by the APLNR gene. This receptor binds apelin and its endogenous ligand, ELABELA, playing critical roles in cardiovascular development, angiogenesis, fluid homeostasis, and metabolic regulation. It activates multiple signaling pathways, including Gαi/o, β-arrestin, and MAPK/ERK, influencing vasodilation, cardiac contractility, and insulin sensitivity. Dysregulation of the apelin-APLNR axis is linked to conditions like hypertension, heart failure, diabetes, and cancer.

APLNR antibodies are widely used in biomedical research to study receptor expression, localization, and function in tissues. They enable techniques like immunohistochemistry, Western blotting, and flow cytometry, helping to map APLNR distribution in endothelial cells, cardiomyocytes, and tumor microenvironments. Some therapeutic antibodies are under exploration to modulate APLNR activity—agonists for cardiovascular repair or antagonists to inhibit pathological angiogenesis in cancers. Challenges include ensuring receptor subtype specificity and minimizing off-target effects due to GPCR structural homology. Recent studies also highlight APLNR's role in COVID-19-related vascular damage, expanding its clinical relevance. These antibodies remain vital for deciphering APLNR's dual roles in physiology and disease, offering potential diagnostic and therapeutic avenues.